GLP-1 receptor agonists have substantially raised the bar for what constitutes meaningful weight loss in obesity trials. For sponsors developing in this space, the central question has shifted from simply whether a drug can reduce body weight to what else it’s doing to the body and whether the protocol is designed to capture it. Put differently, weight loss has become the starting point, not the finish line.
This shift has made five clinical endpoints central to the design of the obesity protocol. Each brings operational decisions that must be addressed during trial feasibility, not after activation.
1. Lean Mass Preservation
Weight loss achieved through GLP-1 mechanisms does not inherently discriminate between fat mass and lean mass. The impact is that patients with significant weight reduction can lose skeletal muscle alongside adipose tissue, and the downstream consequences include functional decline, reduced resting energy expenditure, and increased susceptibility to sarcopenia. Muscle preservation has therefore moved from a secondary observation to a central development objective.
The clinical question is direct. Is this product producing weight loss that protects muscle, or weight loss that the patient may regret a year later?
DEXA gives sponsors a scalable, reproducible read on body composition and is well-suited to large programs, but access to DEXA equipment and trained operators varies across global trial networks. By making strategic site selection and ensuring centralized quality control, trialists can better control variability. As a more accurate, yet more expensive option, MRI-based body composition through platforms like AMRA adds anatomical resolution when distinguishing visceral from subcutaneous fat depots matters to the mechanism story. For example, in a recent Phase IIa obesity program, our team confirmed DEXA availability and stair-elevation specifications for the stair climb test during feasibility rather than at startup. Enrollment finished in two and a half months against a planned four. The 168-subject, 14-site experience is the kind of operational lift that needs to be priced into a protocol before sites are activated.
2. Hepatic Fat
Patients with obesity carry a high background prevalence of metabolic-associated steatotic liver disease (MASLD), and a meaningful proportion of trial participants will present with undiagnosed hepatic steatosis at baseline. GLP-1 mechanisms act on hepatic fat whether liver disease is the primary indication or not, which has moved hepatic endpoints from a co-investigator request into a mainstream secondary endpoint in obesity programs.
Trials must assess whether the drug preferentially reduces visceral and hepatic fat and consider a potential path for label expansion into MASH or fibrosis indications, which could have implications for a broader spectrum of patients when the drug reaches the market.
One popular option, FibroScan®, offers cost-efficient transient elastography for early signal detection at baseline, week 24, and week 52, well-suited to Phase I and IIa work. Another higher-resolution option is MRI-based proton density fat fraction (PDFF), which gives reproducible, quantitative liver fat measurement across imaging centers when later-phase precision is required. Keep in mind that hepatic endpoints require patient stratification at enrollment to account for baseline variability, so observed effects can be confidently attributed to therapy rather than background disease. Sponsors who deliberately plan visceral and hepatic fat measurements at the design stage are creating optionality for a downstream MASH or fibrosis program; sponsors who do not are foreclosing it.
3. Functional Capacity
Body composition changes matter only if they improve patient function. The six-minute walk test, grip strength, sit-to-stand counts, and stair-climb tests have become expected reads in any well-designed obesity protocol because they translate physiological changes into the kind of objective performance metric that regulators, payers, and patients all recognize.
Almost all the operational work is in standardization:
- Grip strength outcomes can vary by device and testing protocol
- Six-minute walk test is sensitive to course layout, environment, and site-level execution
- Stair climb specifications need to be verified site-by-site
Without harmonized protocols and trained operators, functional data carries variance that obscures the drug effect. Site qualification needs to ask these questions before a protocol amendment becomes the only way to fix them.
4. Cardiometabolic Markers
Treating obesity addresses multiple metabolic conditions simultaneously. Blood pressure, lipid profile, fasting glucose, and HbA1c routinely improve alongside weight reduction. For sponsors developing next-generation obesity products, capturing these endpoints inside the obesity program rather than in a separate cardiovascular outcomes study is faster, cheaper, and produces earlier label-relevant data. This requires consideration of whether the mechanism delivers benefit across the metabolic continuum or is simply a single-axis weight-reducing mechanism.
Most of the operational lift is straightforward laboratory work with good QC and sensible visit windows. It is harder when sponsors integrate adjudicated cardiovascular outcomes into an obesity trial. Doing so requires endpoint adjudication committees, clear MACE definitions, event-driven enrollment, and long-duration site relationships that yield low loss to follow-up. Our reference set on CVOT execution at scale includes one program that enrolled 12,000 patients across 473 sites with under 2% loss to follow-up, demonstrating that hybrid obesity-CVOT designs are operationally viable when adjudication infrastructure is built early.
5. Fibrogenesis & Inflammation Biomarkers
Circulating biomarkers complement imaging by providing mechanistic insight into hepatic inflammation, fibrogenesis, and broader metabolic dysfunction. Markers like PRO-C3, transaminases, and lipid panels can be added at modest cost and read longitudinally across visits. The selection should be hypothesis-driven and tied to the specific pathophysiology under investigation, whether fibrosis progression, lipid metabolism, or inflammatory activity. The idea is to discover what biology this mechanism moves beyond the scale.
The operational discipline here is editorial. Obesity is a multi-system disease, which means the universe of available biomarkers is large enough to overload a panel quickly. Sponsors who indiscriminately select biomarkers inflate costs without adding interpretive value. Sponsors who pre-specify markers tied to mechanisms, differentiation strategies, and indication-specific regulatory expectations get cleaner mechanistic stories in the write-up. Using wearables for additional data, a prominent feature of early obesity protocols, has become less central in recent designs as we see sponsors moving toward validated, discrete assessment tools with established reliability.
Implications for Sponsors Designing Now
The shift from a weight-centric protocol to a whole-body protocol is well underway. Sponsors who treat each of these five endpoint categories as a deliberate design choice produce trials that clearly differentiate from regulators, payers, and investors. On the other end, sponsors who continue to optimize for weight alone risk arriving at pivotal results that meet the primary endpoint and still produce limited differentiation in a post-GLP-1 environment. The decisions that determine whether a protocol captures whole-body benefit are made at feasibility, not at startup. The teams running obesity programs well are pulling those questions forward.
For the full clinical and operational treatment of each endpoint, including patient phenotype design, biomarker selection guidance, and regulatory positioning, read our complete white paper: Whole-Body Obesity: The Shift from Weight Loss to Systemic Benefit.
This piece draws on Worldwide Clinical Trials’ May 2026 white paper, “Whole-Body Obesity: The Shift from Weight Loss to Systemic Benefit,” authored by Casey Ustick, Therapeutic Strategy Lead, Cardiometabolic, and Natalia Castro, Executive Director, Cardiovascular & Metabolism, with contribution from Zach Rosinger, PhD.
